Paclitaxel albumin 100mg powder for suspension for infusion vials

ObjectiveTo systematically evaluate the efficacy and safety of albumin-bound paclitaxel and paclitaxel in the treatment of esophageal cancer.MethodsSeven databases (PubMed, Cochrane Library, Embase, China National Knowledge Infrastructure, Wanfang Data, China Science and Technology Journal Database, and China Biology Medicine disc) were searched for randomized controlled trials (RCTs) of albumin-bound paclitaxel and paclitaxel in the treatment of esophageal cancer. The search was conducted from database inception to February 2025. Literature quality was assessed using the Cochrane Risk of Bias Tool version 1 (RoB 1), and the systematic review and meta-analysis was performed using RevMan 5.4.1 and STATA18.ResultsEleven RCTs were included. Meta-analysis demonstrated that albumin-bound paclitaxel significantly improved objective response rate [ORR; relative risk (RR) = 1.67, 95% confidence interval (CI) [1.45, 1.92], p < 0.001, I2 = 0%] and disease control rate (DCR; RR = 1.69, 95% CI [1.43, 1.98], p < 0.001, I2 = 0%) compared to paclitaxel. It also showed superior improvements in serum tumor markers: cancer antigen 125 (CA125) [mean difference (MD) = −1.69, 95% CI [−2.73, −0.65], p < 0.001, I2 = 83%], Carbohydrate antigen 19-9 (CA199) (MD = −2.12, 95% CI [−3.39, −0.84], p = 0.001, I2 = 85%), and carcinoembryonic antigen (CEA) (MD = −2.01, 95% CI [−2.53, −1.50], p < 0.001, I2 = 99%), although Squamous Cell Carcinoma Antigen (SCC) improvement was non-significant (MD = −1.19, 95% CI [−2.61, 0.24], p > 0.001, I2 = 100%). Regarding safety, albumin-bound paclitaxel had markedly lower incidences of diarrhea (RR = 0.49, 95% CI [0.33, 0.72], p = 0.003, I2 = 0%), nausea/vomiting (RR = 0.61, 95% CI [0.46, 0.80], p < 0.001, I2 = 0%), thrombocytopenia (RR = 0.61, 95% CI [0.44, 0.85], p = 0.004, I2 = 22%), and myalgia/arthralgia (RR = 0.45, 95% CI [0.22, 0.94], p = 0.03, I2 = 0%), while neutropenia showed no significant difference (RR = 0.58, 95% CI [0.32, 1.03], p = 0.006, I2 = 0%).ConclusionCompared to paclitaxel, albumin-bound paclitaxel (nab-paclitaxel) demonstrates superior efficacy in the treatment of esophageal cancer, with fewer adverse reactions such as diarrhea, thrombocytopenia, and musculoskeletal pain.

Abstract licence: CC BY 4.0

BackgroundAlthough various effective agents used as second- and third-line treatments for advanced or recurrent small cell lung cancer have improved overall survival, the optimal therapeutic regimen remains controversial. Previous studies have shown that albumin-bound paclitaxel exhibits favorable anticancer activity in many cancer types. However, almost all studies of albumin-bound paclitaxel for recurrent small cell lung cancer are non-randomized controlled trials with small sample sizes, diverse first-line treatment regimens, and non-controlled data analyses. This may result in a lack of valid indicators for evaluating the efficacy and safety of albumin-bound paclitaxel. Therefore, this meta-analysis aims to assess the efficacy and safety of albumin-bound paclitaxel in patients with advanced or recurrent small cell lung cancer.MethodsPubMed, Embase, the Cochrane Library, and Web of Science databases were systematically searched for relevant studies. Outcomes including overall response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and adverse events (AEs) were extracted for further analysis.ResultsNine studies involving 334 patients were enrolled in this meta-analysis. In terms of tumor response, the pooled ORR and DCR were 25.0% and 62.5%, respectively. With regard to survival analysis, the pooled PFS and OS were 3.16 months and 7.23 months, respectively. The most common treatment-related adverse events of nab-paclitaxel were Leukopenia (all grade: 59.3%, ≥grade III: 14.1%), Neutropenia (all grade: 54.9%, ≥grade III: 14.7%), and Anemia (all grade: 53.0%, ≥grade III: 6.2%). Subgroup analysis revealed that combination therapy with immunotherapy was associated with numerically higher response rates and survival.ConclusionsIn summary, this meta-analysis demonstrated that albumin-bound paclitaxel has moderate efficacy and manageable safety in the later-line treatment of advanced or recurrent small cell lung cancer.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/view/CRD420261350933, identifier 420261350933.

Abstract licence: CC BY

Primary pulmonary choriocarcinoma (PPC) is an exceptionally rare and aggressive non-gestational trophoblastic malignancy for which no standard treatment has been established. We report a 61-year-old man with PPC and brain metastases who received intracranial radiotherapy and first-line albumin-bound paclitaxel plus cisplatin, followed by etoposide, capecitabine, and camrelizumab after disease progression. Targeted next-generation sequencing identified loss-of-function or deleterious alterations involving TP53, STK11, KEAP1, and SMARCA4. The second-line immunotherapy-based combination was associated with prolonged extracranial disease control and radiological improvement, although the independent contribution of immune checkpoint inhibition could not be isolated from concurrent chemotherapy and radiotherapy; the disease later progressed intracranially, and the patient ultimately died of intra-abdominal hemorrhage with hepatic metastases. A systematic review of English-language PubMed reports from 2001 to 2026 identified 45 previously reported PPC patients, underscoring the rarity, diagnostic difficulty, aggressive course, and limited evidence base for this disease. Together, this case and literature synthesis suggest that PPC may be clinically and molecularly distinct from gestational choriocarcinoma; however, because these molecular observations derive from a single patient, they should be regarded as hypothesis-generating rather than establishing a general molecular signature of PPC, and that multimodal treatment incorporating immune checkpoint inhibition warrants further investigation in collaborative rare-tumor cohorts.

Abstract licence: CC BY

Platinum-based dual-drug chemotherapy is the standard first-line treatment for non-small cell lung cancer. It inhibits tumor proliferation through cytotoxic effects. However, in clinical practice, 30-40% of patients will experience disease progression due to primary or secondary drug resistance. The present study aimed to analyze the clinical efficacy and adverse reactions of anti-PD-1/L1 + paclitaxel/albumin-paclitaxel + platinum and paclitaxel/albumin-paclitaxel + platinum in the treatment of advanced non-small cell lung cancer. Computer searches were conducted in PubMed, The Cochrane Library, EMbase, China National Knowledge Infrastructure, Wanfang Data, VIPernet and China Biology Medicine databases. Randomized controlled trials on the clinical efficacy of taxel/albumin-paclitaxel + platinum and the combination of taxel/albumin-paclitaxel + platinum immunotherapy drugs in patients with non-small cell lung cancer were collected from the establishment of the database to May 2025. Meta-analysis was conducted using RevMan 5.4 software. A total of five randomized controlled trials were included, involving a total of 3,683 patients. The meta-analysis showed that the median survival rate and the incidence of asymptomatic recurrence in the experimental group (anti-PD-1/L1 + paclitaxel/albumin-paclitaxel + platinum combined immunotherapy drugs) for the treatment of non-small cell lung cancer were higher than those in the control group (paclitaxel/albumin-paclitaxel + platinum). The median progression-free and overall survival time in the experimental group were longer than those in the control group, and the incidence of side effects was higher than that in the control group. The experimental group had advantages in treating non-small cell lung cancer during the asymptomatic remission period and prolonging survival time, but the incidence of adverse reactions decreased.

Abstract licence: CC BY-NC-ND